Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Diseases

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 332 articles:
HTML format
Text format



Single Articles


    February 2019
  1. HOUGHTON D, Zalewski P, Hallsworth K, Cassidy S, et al
    The degree of hepatic steatosis associates with impaired cardiac and autonomic function.
    J Hepatol. 2019 Feb 12. pii: S0168-8278(19)30112.
    PubMed     Text format     Abstract available


  2. TAPPER EB, Romero-Gomez M, Bajaj JS
    Hepatic encephalopathy and traffic accidents: Vigilance is needed!
    J Hepatol. 2019 Feb 11. pii: S0168-8278(19)30031.
    PubMed     Text format    



  3. Corrigendum to "EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma" [J Hepatol 69 (2018) 182-236].
    J Hepatol. 2019 Feb 7. pii: S0168-8278(19)30034.
    PubMed     Text format    


  4. MORTON A
    Splenic artery aneurysms, portal hypertension and pregnancy.
    J Hepatol. 2019 Feb 4. pii: S0168-8278(18)32638.
    PubMed     Text format    


  5. ANDRADE F, Shukla A, Bureau C, Senzolo M, et al
    Reply to: ''Splenic artery aneurysms, portal hypertension and pregnancy".
    J Hepatol. 2019 Feb 4. pii: S0168-8278(19)30017.
    PubMed     Text format    


  6. GANNE-CARRIE N, Nahon P
    Hepatocellular carcinoma in the setting of alcohol-related liver disease.
    J Hepatol. 2019;70:284-293.
    PubMed     Text format     Abstract available


  7. GAO B, Ahmad MF, Nagy LE, Tsukamoto H, et al
    Inflammatory pathways in alcoholic steatohepatitis.
    J Hepatol. 2019;70:249-259.
    PubMed     Text format     Abstract available


  8. BELDI G, Vuitton D, Lachenmayer A, Heyd B, et al
    Is ex vivo liver resection and autotransplantation a valid alternative treatment for end-stage hepatic alveolar echinococcosis in Europe?
    J Hepatol. 2019 Feb 1. pii: S0168-8278(18)32630.
    PubMed     Text format    


    January 2019
  9. BORST K, Graalmann T, Kalinke U
    Reply to: "Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation".
    J Hepatol. 2019 Jan 31. pii: S0168-8278(19)30013.
    PubMed     Text format    


  10. SOLA E, Sole C, Gines P
    Reply to: "Midodrine and albumin in decompensated cirrhosis: Down but not out...".
    J Hepatol. 2019 Jan 30. pii: S0168-8278(18)32646.
    PubMed     Text format    


  11. SANZ-GARCIA C, Poulsen KL, Bellos D, Wang H, et al
    The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute on chronic ethanol administration in mice.
    J Hepatol. 2019 Jan 30. pii: S0168-8278(19)30064.
    PubMed     Text format     Abstract available


  12. KESSLER SM, Hoppstadter J, Hosseini K, Laggai S, et al
    Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation.
    J Hepatol. 2019 Jan 24. pii: S0168-8278(18)32569.
    PubMed     Text format    


  13. FERRARESE A, Feltracco P, Barbieri S, Cillo U, et al
    Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(18)32389.
    PubMed     Text format    


  14. VAN DER MERWE S, Laleman W, Langouche L, Meersseman P, et al
    Reply to: "Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF".
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30007.
    PubMed     Text format    


  15. SINGH V, Singh A, Agarwal R
    Midodrine and albumin in decompensated cirrhosis: Down but not out....
    J Hepatol. 2019 Jan 23. pii: S0168-8278(18)32540.
    PubMed     Text format    


  16. XIANG X, Wang Y, Mo DC, Wang SQ, et al
    Liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection: A comment for moving forward.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(18)32572.
    PubMed     Text format    


  17. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30015.
    PubMed     Text format     Abstract available


  18. WEI W, Li L, Kong G, Zheng Z, et al
    Spleen in hepatocellular carcinoma: More complexity and importance than we knew.
    J Hepatol. 2019 Jan 22. pii: S0168-8278(18)32573.
    PubMed     Text format    


  19. GRANCINI V, Trombetta M, Lunati ME, Boselli ML, et al
    Central role of the beta-cell in driving regression of diabetes after liver transplantation in cirrhotic patients.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(19)30028.
    PubMed     Text format     Abstract available


  20. GWAG T, Meng Z, Sui Y, Helsley RN, et al
    Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(19)30029.
    PubMed     Text format     Abstract available


  21. PAUMELLE R, Haas J, Hennuyer N, Bauge E, et al
    Hepatic PPARalpha is critical in the metabolic adaptation to sepsis.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(19)30027.
    PubMed     Text format     Abstract available


  22. HUO TI, Liu PH, Hsu CY
    Predicting post-resection recurrence of hepatocellular carcinoma: Spleen stiffness vs. ALBI grade.
    J Hepatol. 2019 Jan 21. pii: S0168-8278(18)32571.
    PubMed     Text format    


  23. MARASCO G, Colecchia A, Colli A, Ravaioli F, et al
    Reply to correspondence concerning: "Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection".
    J Hepatol. 2019 Jan 17. pii: S0168-8278(18)32645.
    PubMed     Text format    


  24. WANG Q, Xia D, Bai W, Wang E, et al
    Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study.
    J Hepatol. 2019 Jan 17. pii: S0168-8278(19)30025.
    PubMed     Text format     Abstract available


  25. BARAHMAN M, Zhang W, Yaffe Harris H, Aiyer A, et al
    Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30022.
    PubMed     Text format     Abstract available


  26. XU QG, Yuan SX, Tao QF, Yu J, et al
    A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30018.
    PubMed     Text format     Abstract available


  27. VAN WETTERE M, Purcell Y, Bruno O, Payance A, et al
    Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30021.
    PubMed     Text format     Abstract available


  28. HSU YC, Yip TC, Ho HJ, Wong VW, et al
    Corrigendum to "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B" [J Hepatol 69 (2018) 278-285].
    J Hepatol. 2019 Jan 8. pii: S0168-8278(18)32629.
    PubMed     Text format    


  29. HSU YC, Yip TC, Wong GL, Wu CY, et al
    Reply to: "Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues".
    J Hepatol. 2019 Jan 8. pii: S0168-8278(18)32583.
    PubMed     Text format    


  30. FORMENTIN C, De Rui M, Zoncape M, Ceccato S, et al
    The Psychomotor Vigilance Task: Role in the Diagnosis of Hepatic Encephalopathy and Relationship with Driving Ability.
    J Hepatol. 2019 Jan 8. pii: S0168-8278(19)30005.
    PubMed     Text format     Abstract available


  31. WU F, Wu D, Ren Y, Huang Y, et al
    Generation of hepato-biliary organoids from human induced pluripotent stem cells.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30002.
    PubMed     Text format     Abstract available


  32. YOO JJ, Kim SG, Kim YS, Lee B, et al
    Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30004.
    PubMed     Text format     Abstract available


  33. GOLDARACENA N, Gorgen A, Doyle A, Hansen BE, et al
    Live Donor Liver Transplantation for Patients with Hepatocellular Carcinoma Offers Increased Survival vs. Deceased Donation.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30003.
    PubMed     Text format     Abstract available


  34. TISCHENDORF M, Fuchs A, Zeuzem S, Lange CM, et al
    Use of prothrombin complex concentrates in patients with decompensated liver cirrhosis is associated with thromboembolic events.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(18)32570.
    PubMed     Text format    


  35. TSAI JF, Perng DS
    Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(18)32546.
    PubMed     Text format    


  36. ZHANG Y, Pei Y, Chen X, Zhang W, et al
    Treatment for solitary hepatocellular carcinoma ranging from 2 and 5cm: Is the curative effect of no-touch multibipolar radiofrequency ablation comparable to that of surgical resection?
    J Hepatol. 2019 Jan 4. pii: S0168-8278(18)32524.
    PubMed     Text format    


  37. HADJIHAMBI A, Harrison IF, Costas-Rodriguez M, Vanhaecke F, et al
    Corrigendum to "Impaired brain glymphatic flow in experimental hepatic encephalopathy" [J Hepatol 69 (2019) 40-49].
    J Hepatol. 2019 Jan 4. pii: S0168-8278(18)32631.
    PubMed     Text format    


  38. QIN JJ, Mao W, Wang X, Sun P, et al
    Corrigendum to "Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1" [J Hepatol 69 (2018) 1110-1122].
    J Hepatol. 2019 Jan 4. pii: S0168-8278(18)32522.
    PubMed     Text format    


  39. DOYLE A, Gorgen A, Muaddi H, Aravinthan AD, et al
    Outcomes of Radiofrequency Ablation as First-Line Therapy for Hepatocellular Carcinoma less than 3 cm in Potentially Transplantable Patients.
    J Hepatol. 2019 Jan 4. pii: S0168-8278(19)30001.
    PubMed     Text format     Abstract available


    December 2018
  40. MOHKAM K, Mabrut JY
    Reply to: "Treatment for solitary hepatocellular carcinoma ranging from 2 and 5cm: Is the curative effect of no-touch multibipolar radiofrequency ablation comparable to that of surgical resection?"
    J Hepatol. 2018 Dec 24. pii: S0168-8278(18)32579.
    PubMed     Text format    


  41. TSAY HC, Yuan Q, Balakrishnan A, Kaiser M, et al
    Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis.
    J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32635.
    PubMed     Text format     Abstract available


  42. BAUMEISTER SE, Schlesinger S, Aleksandrova K, Jochem C, et al
    Association of Physical Activity and Risk of Hepatobiliary Cancers: A Multinational Cohort Study.
    J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32633.
    PubMed     Text format     Abstract available


  43. ZHANG YM, Zhou ZT, Liu GM
    Factors predicting early recurrence after surgical resection of hepatocellular carcinoma.
    J Hepatol. 2018 Dec 19. pii: S0168-8278(18)32523.
    PubMed     Text format    


  44. CHAN AWH, Berhane S, Cucchetti A, Johnson PJ, et al
    Reply to: Correspondence concerning "Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection".
    J Hepatol. 2018 Dec 18. pii: S0168-8278(18)32577.
    PubMed     Text format    


  45. DE OLIVEIRA S, Houseright RA, Graves AL, Golenberg N, et al
    Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
    J Hepatol. 2018 Dec 17. pii: S0168-8278(18)32622.
    PubMed     Text format     Abstract available


  46. KUSAKABE J, Firl DJ, Sasaki K
    Toward the universal scoring system in treatment for patients with hepatocellular carcinoma.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32508.
    PubMed     Text format    


  47. ZHANG XY, Ou J, Chen JY, Li WW, et al
    Predicting early hepatocellular carcinoma recurrence after resection: A comment for moving forward.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32491.
    PubMed     Text format    


  48. RINELLA ME, Trotter JF, Abdelmalek MF, Paredes AH, et al
    Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with nonalcoholic steatohepatitis.
    J Hepatol. 2018 Dec 7. pii: S0168-8278(18)32615.
    PubMed     Text format     Abstract available


  49. PARK JW, Kim YJ, Kim DY, Bae SH, et al
    Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: a phase III STAH trial.
    J Hepatol. 2018 Dec 5. pii: S0168-8278(18)32580.
    PubMed     Text format     Abstract available


  50. BOEREKAMPS A, Vanwolleghem T, van der Valk M, van den Berk GE, et al
    8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).
    J Hepatol. 2018 Dec 5. pii: S0168-8278(18)32516.
    PubMed     Text format    


    November 2018
  51. STAMM LM, Brainard DM, McHutchison JG
    Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Nov 13. pii: S0168-8278(18)32528.
    PubMed     Text format    



  52. Reply to: "Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018".
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32529.
    PubMed     Text format    


  53. OTETE H, Deleuran T, Fleming KM, Card T, et al
    Reply to: "Hip fracture risk in patients with alcoholic cirrhosis: Do comorbidities and complications matter?"
    J Hepatol. 2018 Nov 10. pii: S0168-8278(18)32459.
    PubMed     Text format    


  54. YU SJ, Ma C, Heinrich B, Brown ZJ, et al
    Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32525.
    PubMed     Text format     Abstract available


  55. WEISS N, Housset C, Thabut D
    Hepatic encephalopathy: Another brick in the wall.
    J Hepatol. 2018 Nov 7. pii: S0168-8278(18)32499.
    PubMed     Text format    


  56. FERNANDEZ J, Prado V, Trebicka J, Amoros A, et al
    Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe.
    J Hepatol. 2018 Nov 1. pii: S0168-8278(18)32511.
    PubMed     Text format     Abstract available


    October 2018
  57. RAVEN A, Forbes SJ
    Hepatic progenitors in liver regeneration.
    J Hepatol. 2018 Oct 31. pii: S0168-8278(18)30154.
    PubMed     Text format    


  58. ZHAO LY, Luo YJ, Zhu J, Liu HY, et al
    Hip fracture risk in patients with alcoholic cirrhosis: Do comorbidities and complications matter?
    J Hepatol. 2018 Oct 31. pii: S0168-8278(18)32386.
    PubMed     Text format    


  59. METWALLY M, Bayoumi A, Romero-Gomez M, Thabet K, et al
    A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32505.
    PubMed     Text format     Abstract available


  60. MARASCO G, Colecchia A, Colli A, Ravaioli F, et al
    Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32506.
    PubMed     Text format     Abstract available


  61. KIM HY, So YH, Kim W, Ahn DW, et al
    Noninvasive Response Prediction in Prophylactic Carvedilol Therapy for Cirrhotic Patients with Esophageal Varices.
    J Hepatol. 2018 Oct 30. pii: S0168-8278(18)32502.
    PubMed     Text format     Abstract available


  62. YIP TC, Wong GL, Chan HL, Tse YK, et al
    HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    J Hepatol. 2018 Oct 24. pii: S0168-8278(18)32497.
    PubMed     Text format     Abstract available


  63. IOANNOU GN
    Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment".
    J Hepatol. 2018 Oct 19. pii: S0168-8278(18)32445.
    PubMed     Text format    


  64. JI F, Yeo YH, He C, Li J, et al
    Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment.
    J Hepatol. 2018 Oct 15. pii: S0168-8278(18)32390.
    PubMed     Text format    


  65. D'AMICO G, Bataller R
    Need for surveillance of hepatocellular carcinoma in patients with alcoholic cirrhosis.
    J Hepatol. 2018 Oct 11. pii: S0168-8278(18)32447.
    PubMed     Text format    


  66. O'BRIEN A, Kamath PS, Trotter J
    MACHT - Outpatient albumin infusions do not prevent complications of cirrhosis in patients on the liver transplant waiting list.
    J Hepatol. 2018 Oct 9. pii: S0168-8278(18)32444.
    PubMed     Text format    


  67. JAYAKUMAR S, Middleton MS, Lawitz EJ, Mantry PS, et al
    Longitudinal Correlations Between MRE, MRI-PDFF, and Liver Histology in Patients with Nonalcoholic Steatohepatitis: Analysis of Data from a Phase 2 Trial of Selonsertib.
    J Hepatol. 2018 Oct 3. pii: S0168-8278(18)32443.
    PubMed     Text format     Abstract available


  68. GIANNINI EG, Bodini G, Furnari M, Marabotto E, et al
    NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis.
    J Hepatol. 2018;69:972-973.
    PubMed     Text format    


  69. DE FRANCHIS R, Krag A
    Ruling out esophageal varices in NAFLD cirrhosis: Can we do without endoscopy?
    J Hepatol. 2018;69:769-771.
    PubMed     Text format    


  70. CHEN Y, Chen HN, Wang K, Zhang L, et al
    Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.
    J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32441.
    PubMed     Text format     Abstract available


  71. SAGGI H, Maitra D, Jiang A, Zhang R, et al
    Loss of hepatocyte beta-Catenin protects mice from experimental porphyria-associated liver injury.
    J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32442.
    PubMed     Text format     Abstract available


    September 2018
  72. DEUGNIER Y, Morcet J, Laine F, Hamdi-Roze H, et al
    Reduced phenotypic expression in genetic hemochromatosis with time: role of exposure to nongenetic modifiers.
    J Hepatol. 2018 Sep 20. pii: S0168-8278(18)32383.
    PubMed     Text format     Abstract available


  73. LOW JTS, Rohde G, Pittordou K, Candy B, et al
    Supportive and palliative care in people with cirrhosis: international systematic review of the perspective of patients, family members and health professionals.
    J Hepatol. 2018 Sep 19. pii: S0168-8278(18)32381.
    PubMed     Text format     Abstract available


  74. KIM Y, Kang K, Lee SB, Seo D, et al
    Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells.
    J Hepatol. 2018 Sep 18. pii: S0168-8278(18)32380.
    PubMed     Text format     Abstract available


  75. CHAN AWH, Zhong J, Berhane S, Toyoda H, et al
    Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.
    J Hepatol. 2018 Sep 17. pii: S0168-8278(18)32378.
    PubMed     Text format     Abstract available


  76. ZHANG T, Hu J, Wang X, Zhao X, et al
    MicroRNA-378 Promotes Hepatic Inflammation and Fibrosis via Modulation of the NFkappaB-TNFalpha Pathway.
    J Hepatol. 2018 Sep 12. pii: S0168-8278(18)32376.
    PubMed     Text format     Abstract available


  77. CALDERARO J, Petitprez F, Becht E, Laurent A, et al
    Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
    J Hepatol. 2018 Sep 10. pii: S0168-8278(18)32373.
    PubMed     Text format     Abstract available


  78. TORGERSON PR, Schweiger A, Deplazes P, Pohar M, et al
    Corrigendum to "Alveolar echinococcosis: From a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35years" [J Hepatol 49 (2008) 72-77].
    J Hepatol. 2018 Sep 8. pii: S0168-8278(18)32292.
    PubMed     Text format    


  79. SHEARER J, Chizhande D, Jones R, Rowe IA, et al
    Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease.
    J Hepatol. 2018 Sep 8. pii: S0168-8278(18)32282.
    PubMed     Text format    


  80. HADJIHAMBI A, Harrison IF, Costas-Rodriguez M, Vanhaecke F, et al
    Impaired brain glymphatic flow in experimental hepatic encephalopathy.
    J Hepatol. 2018 Sep 7. pii: S0168-8278(18)32367.
    PubMed     Text format     Abstract available


  81. GUSTOT T, Moreau R
    Acute-on-Chronic Liver Failure vs. Traditional Acute Decompensation of Cirrhosis.
    J Hepatol. 2018 Sep 6. pii: S0168-8278(18)32370.
    PubMed     Text format     Abstract available


  82. PETTA S, Sebastiani G, de Ledinghen V
    Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease".
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32300.
    PubMed     Text format    


  83. GJORGJIEVA M, Calderaro J, Monteillet L, Silva M, et al
    Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.
    J Hepatol. 2018 Sep 4. pii: S0168-8278(18)32271.
    PubMed     Text format     Abstract available


  84. MERLI M, Durand F
    Muscle mass vs. adipose tissue to predict outcome in cirrhosis: Which matters and in which patients?
    J Hepatol. 2018;69:567-569.
    PubMed     Text format    


    August 2018

  85. Corrigendum to "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis" [J Hepatol 69 (2018) 406-460].
    J Hepatol. 2018 Aug 29. pii: S0168-8278(18)32290.
    PubMed     Text format    


  86. YOUNOSSI Z, Stepanova M, Sanyal AJ, Harrison SA, et al
    The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options.
    J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32295.
    PubMed     Text format     Abstract available


  87. MOREAU R, Bataller R, Berg T, Lotersztajn S, et al
    Corrigendum to "From the Editor's Desk August 2018" [J Hepatol 69 (2018) 265-268].
    J Hepatol. 2018 Aug 21. pii: S0168-8278(18)32281.
    PubMed     Text format    


  88. ANDRADE F, Shukla A, Bureau C, Senzolo M, et al
    Pregnancy in Idiopathic Non-Cirrhotic Portal Hypertension: A Multicentric Study on Maternal and Fetal Management and Outcome.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32286.
    PubMed     Text format     Abstract available


  89. CLARK VC, Marek G, Liu C, Collinsworth A, et al
    Clinical and Histologic Features of Adults with Alpha-1 Antitrypsin Deficiency in a Non-Cirrhotic Cohort.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32284.
    PubMed     Text format     Abstract available


  90. IOANNOU GN, Green PK, Beste LA, Mun EJ, et al
    Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32287.
    PubMed     Text format     Abstract available


  91. SOLA E, Sole C, Simon-Talero M, Martin-Llahi M, et al
    MIDODRINE &ALBUMIN for Preventing COMPLICATIONS IN PATIENTS WITH CIRRHOSIS AWAITING Liver transplantation.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32285.
    PubMed     Text format     Abstract available


  92. BRUIX J, Cheng AL, Meinhardt G, Nakajima K, et al
    Corrigendum to "Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies" [J hepatol 67 (2017) 999-1008].
    J Hepatol. 2018 Aug 10. pii: S0168-8278(18)32269.
    PubMed     Text format    


  93. ASRANI SK, Saracino G, O'Leary JG, Gonzalez S, et al
    Corrigendum to "Recipient characteristics and morbidity and mortality after liver transplantation" [J hepatol 69 (2018) 43-50].
    J Hepatol. 2018 Aug 7. pii: S0168-8278(18)32268.
    PubMed     Text format    


  94. YANG X, Chen J, Wang N, Liu Z, et al
    Clinical use of dendritic cell-derived exosomes for hepatocellular carcinoma immunotherapy: How far we are?
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32183.
    PubMed     Text format    


  95. GANNE-CARRIE N, Chaffaut C, Bourcier V, Archambeaud I, et al
    Estimate of hepatocellular carcinoma's incidence in patients with alcoholic cirrhosis.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32278.
    PubMed     Text format     Abstract available


  96. TSUCHIDA T, Lee YA, Fujiwara N, Ybanez M, et al
    Corrigendum to "A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer" [J Hepatol 69 (2018) 385-395].
    J Hepatol. 2018 Aug 3. pii: S0168-8278(18)32263.
    PubMed     Text format    


    July 2018
  97. KIM JH, Kim YD, Lee M, Jun BG, et al
    Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
    J Hepatol. 2018 Jul 31. pii: S0168-8278(18)32274.
    PubMed     Text format     Abstract available


  98. MAROT A, Henrion J, Knebel JF, Deltenre P, et al
    Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis.
    J Hepatol. 2018 Jul 23. pii: S0168-8278(18)32160.
    PubMed     Text format    


  99. AJI T, Dong JH, Shao YM, Zhao JM, et al
    Ex vivo Liver Resection and Autotransplantation as Alternative to Allotransplantation for End-stage Hepatic Alveolar Echinococcosis.
    J Hepatol. 2018 Jul 19. pii: S0168-8278(18)32258.
    PubMed     Text format     Abstract available


  100. SCOTT CL, Guilliams M
    The role of Kupffer cells in hepatic iron and lipid metabolism.
    J Hepatol. 2018 Jul 9. pii: S0168-8278(18)30130.
    PubMed     Text format    


  101. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Reply to: "NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis": Cryptogenic cirrhosis should not be equated with NASH cirrhosis based on UNOS data mining and Bayesian 'doctrine of chances'.
    J Hepatol. 2018 Jul 5. pii: S0168-8278(18)32168.
    PubMed     Text format    


  102. PLOTON M, Mazuy C, Gheeraert C, Dubois V, et al
    The Nuclear Bile Acid Receptor FXR is a PKA- and FOXA2-Sensitive Activator of Fasting Hepatic Gluconeogenesis.
    J Hepatol. 2018 Jul 4. pii: S0168-8278(18)32175.
    PubMed     Text format     Abstract available


  103. LAI SW, Lin CL, Liao KF
    Association between cirrhosis and hip fracture in older people in a population-based cohort study.
    J Hepatol. 2018 Jul 2. pii: S0168-8278(18)32060.
    PubMed     Text format    


    June 2018
  104. TANDON P, Ismond KP, Riess K, Duarte-Rojo A, et al
    Exercise in Cirrhosis: Translating evidence and experience to practice.
    J Hepatol. 2018 Jun 28. pii: S0168-8278(18)32170.
    PubMed     Text format     Abstract available


  105. FUHRMANN V, Krowka M
    Hepatopulmonary syndrome.
    J Hepatol. 2018 Jun 27. pii: S0168-8278(18)30007.
    PubMed     Text format    


  106. QIN JJ, Mao W, Wang X, Sun P, et al
    Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1.
    J Hepatol. 2018 Jun 26. pii: S0168-8278(18)32167.
    PubMed     Text format     Abstract available


  107. YU JJ, Li JD, Xu XF, Shen F, et al
    Is obesity a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis?
    J Hepatol. 2018 Jun 8. pii: S0168-8278(18)32061.
    PubMed     Text format    


  108. BRADLEY CR, Cox EF, Scott RA, James MW, et al
    Multi organ assessment of Compensated Cirrhosis Patients using quantitative Magnetic Resonance Imaging.
    J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32122.
    PubMed     Text format     Abstract available


  109. TONG M, Che N, Zhou L, Luk ST, et al
    Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    J Hepatol. 2018 Jun 6. pii: S0168-8278(18)32119.
    PubMed     Text format     Abstract available


  110. SEGERITZ CP, Rashid ST, Cardoso de Brito M, Paola MS, et al
    hiPSC hepatocyte model demonstrates the role of unfolded protein response and inflammatory networks in alpha1-antitrypsin deficiency.
    J Hepatol. 2018 Jun 4. pii: S0168-8278(18)32113.
    PubMed     Text format     Abstract available


  111. TURCO L, Garcia-Tsao G, Rossi R, Villa E, et al
    Reply to "The Relationship of Hyperdynamic Circulation and Cardiodynamic States in Cirrhosis".
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32101.
    PubMed     Text format    


  112. NAKAMURA K, Zhang M, Kageyama S, Ke B, et al
    Protective effects of heme oxygenase 1 during ischemia r epefrfsuion injury: Hepatocytes or non parenchymal cells?
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32114.
    PubMed     Text format    


  113. LEE S, Kang TW
    Reply to "Influence of ablation technique on treatment failure for perivascular hepatocellular carcinoma".
    J Hepatol. 2018 Jun 2. pii: S0168-8278(18)32117.
    PubMed     Text format    


    May 2018
  114. SUNDARAM V, Goldberg DS, Jalan R
    Author response: Is obesity a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis?
    J Hepatol. 2018 May 31. pii: S0168-8278(18)32100.
    PubMed     Text format    


  115. MOHKAM K, Rode A, Mabrut JY
    Influence of ablation technique on treatment failure for perivascular hepatocellular carcinoma.
    J Hepatol. 2018 May 25. pii: S0168-8278(18)32045.
    PubMed     Text format    


  116. PETTA S, Sebastiani G, Bugianesi E, Vigano M, et al
    Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32065.
    PubMed     Text format     Abstract available


  117. LE GUILCHER C, Garcin I, Dellis O, Cauchois F, et al
    The P2X4 purinergic receptor regulates hepatic myofibroblast activation during liver fibrogenesis.
    J Hepatol. 2018 May 23. pii: S0168-8278(18)32066.
    PubMed     Text format     Abstract available


  118. ALVARADO E, Garcia-Guix M, Mirabet S, Villanueva C, et al
    The relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis.
    J Hepatol. 2018 May 18. pii: S0168-8278(18)32044.
    PubMed     Text format    


  119. XU D, Xu M, Kong X, Xia Q, et al
    Protective effects of heme oxygenase 1 during ischemia-reperfusion injury: Hepatocytes or non-parenchymal cells?
    J Hepatol. 2018 May 17. pii: S0168-8278(18)32046.
    PubMed     Text format    


  120. NOORDZIJ W, de Jong KP, de Meijer VE
    Response to: Positron emission tomography/computed tomography with (18)F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
    J Hepatol. 2018 May 17. pii: S0168-8278(18)32024.
    PubMed     Text format    


  121. BANERJEE R, Kelly M, Wilman H, Wright T, et al
    Imaging endpoints for non-alcoholic steatohepatitis (NASH) therapeutic trials: A growing role for multiparametric MRI?
    J Hepatol. 2018 May 16. pii: S0168-8278(18)32033.
    PubMed     Text format    


  122. SUAREZ-AMARAN L, Usai C, Di Scala M, Godoy C, et al
    Erratum to "A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-beta induction" [J Hepatol 67 (2017) 669-679].
    J Hepatol. 2018 May 15. pii: S0168-8278(18)32010.
    PubMed     Text format    


  123. PATNAIK MM, Kamath PS, Simonetto DA
    Grand Rounds: Hepatic Manifestations of Telomere Biology Disorders.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32052.
    PubMed     Text format     Abstract available


  124. WONG GL, Chan HL, Tse YK, Yip TC, et al
    Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32055.
    PubMed     Text format     Abstract available


  125. ORRU C, Szydlowska M, Taguchi K, Zavattari P, et al
    Genetic inactivation of Nrf2 prevents clonal expansion of initiated cells in a nutritional model of rat hepatocarcinogenesis.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32056.
    PubMed     Text format     Abstract available


  126. OH SH, Swiderska-Syn M, Jewell ML, Premont RT, et al
    Liver regeneration requires Yap1-TGFbeta-dependent epithelial-mesenchymal transition in hepatocytes.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32054.
    PubMed     Text format     Abstract available


    April 2018
  127. CHALAYE J, Costentin CE, Luciani A, Nault JC, et al
    Reply to "PET/CT with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma".
    J Hepatol. 2018 Apr 29. pii: S0168-8278(18)32031.
    PubMed     Text format    


  128. MOLLER S, Lee SS
    Cirrhotic cardiomyopathy.
    J Hepatol. 2018 Apr 28. pii: S0168-8278(18)30017.
    PubMed     Text format    


  129. EBADI M, Tandon P, Moctezuma-Velazquez C, Ghosh S, et al
    Low Subcutaneous Adiposity Associates with Higher Mortality in Female Patients with Cirrhosis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32026.
    PubMed     Text format     Abstract available


  130. SUNDARAM V, Jalan R, Ahn JC, Charlton MR, et al
    Class III obesity is a risk factor for the development of acute on chronic liver failure in patients with decompensated cirrhosis.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32027.
    PubMed     Text format     Abstract available


  131. ZHAO L, Zhang C, Luo X, Wang P, et al
    CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32014.
    PubMed     Text format     Abstract available


  132. SPOSITO C, Spreafico C, Mazzaferro V
    Re: validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32016.
    PubMed     Text format    


  133. OTETE H, Deleuran T, Fleming KM, Card TR, et al
    Hip fracture risk in patients with alcoholic cirrhosis: a population-based study using English and Danish data.
    J Hepatol. 2018 Apr 16. pii: S0168-8278(18)31978.
    PubMed     Text format     Abstract available


  134. WIEST R, Albillos A, Trauner M, Bajaj JS, et al
    Corrigendum to "Targeting the gut-liver axis in liver disease" [J Hepatol 67 (2017) 1084-1103].
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)30149.
    PubMed     Text format    



  135. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
    J Hepatol. 2018 Apr 10. pii: S0168-8278(18)31966.
    PubMed     Text format    



  136. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
    J Hepatol. 2018 Apr 5. pii: S0168-8278(18)30215.
    PubMed     Text format    


  137. LUCIDI C, Lattanzi B, Riggio O, Merli M, et al
    May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?
    J Hepatol. 2018 Apr 4. pii: S0168-8278(18)30213.
    PubMed     Text format    


  138. VAN VUGT JLA, Alferink LJM, Buettner S, Metselaar HJ, et al
    Reply to: "May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?" and "Has the time come for using MELD-Sarcopenia score?"
    J Hepatol. 2018 Apr 3. pii: S0168-8278(18)30212.
    PubMed     Text format    


  139. BAJAJ JS
    Hepatic encephalopathy: classification and treatment.
    J Hepatol. 2018;68:838-839.
    PubMed     Text format    


    March 2018
  140. TSUCHIDA T, Lee YA, Fujiwara N, Ybanez M, et al
    A Simple Diet- and Chemical-Induced Murine NASH Model with Rapid Progression of Steatohepatitis, Fibrosis and Liver Cancer.
    J Hepatol. 2018 Mar 20. pii: S0168-8278(18)30175.
    PubMed     Text format     Abstract available


  141. TURNER AM, Stolk J, Bals R, Lickliter J, et al
    Hepatic-targeted RNA interference provides persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.
    J Hepatol. 2018 Mar 20. pii: S0168-8278(18)30176.
    PubMed     Text format     Abstract available


  142. KONERMAN MA, Jones JC, Harrison SA
    Corrigendum to "Pharmacotherapy for NASH: Current and emerging" [J Hepatol 68 (2017) 362-375].
    J Hepatol. 2018 Mar 19. pii: S0168-8278(18)30150.
    PubMed     Text format    


  143. PEREYRA D, Starlinger P
    Intra Platelet Serotonin Affects Overall Survival in Hepatocellular Cancer Patients.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30166.
    PubMed     Text format    


  144. HSU YC, Cheuk-Fung Yip T, Ho HJ, Wai-Sun Wong V, et al
    Development of a scoring system to Predict Hepatocellular Carcinoma in Asians on Antivirals for Chronic Hepatitis B.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30170.
    PubMed     Text format     Abstract available


  145. ROMANO A, Angeli P, Piovesan S, Noventa F, et al
    "Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study".
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30172.
    PubMed     Text format     Abstract available


  146. PUOTI M, Foster GR, Wang S, Mutimer D, et al
    High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30165.
    PubMed     Text format     Abstract available


  147. DONG LQ, Shi Y, Ma LJ, Yang LX, et al
    Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30167.
    PubMed     Text format     Abstract available


  148. MOSCONI C, Cucchetti A, Pettinato C, Golfieri R, et al
    Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    J Hepatol. 2018 Mar 13. pii: S0168-8278(18)30151.
    PubMed     Text format    


  149. ABITBOL S, Dahmani R, Coulouarn C, Ragazzon B, et al
    AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of beta-catenin activation.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(17)32534.
    PubMed     Text format     Abstract available


  150. LEE S, Kang TW, Cha DI, Song KD, et al
    Radiofrequency ablation versus surgery for perivascular hepatocellular carcinoma: propensity score analyses of long-term outcomes.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30148.
    PubMed     Text format     Abstract available


  151. ZHANG Z, Filzmayer C, Ni Y, Sultmann H, et al
    Hepatitis D Virus replication is sensed by MDA5 and induces IFN-beta/lambda responses in hepatocytes.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30143.
    PubMed     Text format     Abstract available


  152. CHALAYE J, Costentin CE, Luciani A, Amaddeo G, et al
    Positron emission tomography / computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
    J Hepatol. 2018 Mar 5. pii: S0168-8278(18)30136.
    PubMed     Text format     Abstract available


  153. LIU JJ, Li Y, Chen WS, Liang Y, et al
    Shp2 Deletion in Hepatocytes Suppresses Hepatocarcinogenesis Driven by Oncogenic beta-Catenin, PIK3CA and MET.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30131.
    PubMed     Text format     Abstract available


  154. NAULT JC, Galle PR, Marquardt JU
    The role of molecular enrichment on future therapies in hepatocellular carcinoma.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30134.
    PubMed     Text format     Abstract available


  155. KARLSEN TH, Tacke F
    <<The times they are a'changin'>> - Positioning the European Association for the Study of the Liver in the changing landscape of hepatology.
    J Hepatol. 2018 Mar 1. pii: S0168-8278(18)30112.
    PubMed     Text format    


    February 2018
  156. SHA M, Jeong S, Xia Q
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection: Novel Concerns.
    J Hepatol. 2018 Feb 20. pii: S0168-8278(18)30122.
    PubMed     Text format    


  157. LYU N, Kong Y, Mu L, Lin Y, et al
    Hepatic Arterial Infusion of Oxaliplatin plus Fluorouracil/Leucovorin versus Sorafenib for Advanced Hepatocellular Carcinoma.
    J Hepatol. 2018 Feb 19. pii: S0168-8278(18)30125.
    PubMed     Text format     Abstract available


  158. LI J, Lei Z, Wang K, Shen F, et al
    Reply to "Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection: novel concerns".
    J Hepatol. 2018 Feb 17. pii: S0168-8278(18)30127.
    PubMed     Text format    


  159. COENRAAD MJ, Porcher R, Bendtsen F
    Hepatic and cardiac hemodynamics and systemic inflammation in cirrhosis: it takes three to tango.
    J Hepatol. 2018 Feb 17. pii: S0168-8278(18)30124.
    PubMed     Text format     Abstract available


  160. NISHIZAWA N, Ito Y, Eshima K, Ohkubo H, et al
    Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice.
    J Hepatol. 2018 Feb 16. pii: S0168-8278(18)30126.
    PubMed     Text format     Abstract available


  161. DUAN F, Wu H, Jia D, Wu W, et al
    O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis.
    J Hepatol. 2018 Feb 14. pii: S0168-8278(18)30119.
    PubMed     Text format     Abstract available


  162. ZHANG P, Ge Z, Wang H, Feng W, et al
    Prolactin improves hepatic steatosis via CD36 pathway.
    J Hepatol. 2018 Feb 13. pii: S0168-8278(18)30115.
    PubMed     Text format     Abstract available


  163. YOON YI, Song GW, Lee SG, Hwang S, et al
    Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.
    J Hepatol. 2018 Feb 13. pii: S0168-8278(18)30113.
    PubMed     Text format     Abstract available


  164. GUIU B, Jouve JL, Schmitt A, Minello A, et al
    Intra-arterial Idarubicin_lipiodol without embolization in hepatocellular carcinoma: the LIDA-B phase I trial.
    J Hepatol. 2018 Feb 7. pii: S0168-8278(18)30069.
    PubMed     Text format     Abstract available


  165. KIM AY, Sinn DH, Jeong WK, Kim YK, et al
    Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma.
    J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30071.
    PubMed     Text format     Abstract available


  166. MOHKAM K, Dumont PN, Manichon AF, Jouvet JC, et al
    No touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm.
    J Hepatol. 2018 Feb 1. pii: S0168-8278(18)30057.
    PubMed     Text format     Abstract available


  167. LIM C, Salloum C, Azoulay D
    Reply to Letter: "Liver resection for BCLC 0-A stage hepatocellular carcinoma: does the time to surgery not impact the prognosis".
    J Hepatol. 2018 Feb 1. pii: S0168-8278(18)30067.
    PubMed     Text format    


    January 2018
  168. PEI Y, Chen X, Zhang W
    Liver resection for BCLC 0-A stage hepatocellular carcinoma: does the time to surgery not impact the prognosis?
    J Hepatol. 2018 Jan 31. pii: S0168-8278(18)30065.
    PubMed     Text format    


  169. BUREAU C, Adebayo D, de Rieu MC, Elkrief L, et al
    Corrigendum to "Alfapump(R) system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study" [J Hepatol 67 (2017) 940-949].
    J Hepatol. 2018 Jan 29. pii: S0168-8278(17)32532.
    PubMed     Text format    


  170. YU J, Xu QG, Wang ZG, Yang Y, et al
    Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma.
    J Hepatol. 2018 Jan 26. pii: S0168-8278(18)30055.
    PubMed     Text format     Abstract available


  171. GEHRKE N, Hovelmeyer N, Waisman A, Straub BK, et al
    Hepatocyte-specific deletion of IL1-RI attenuatesliver injury by blocking IL-1 driven autoinflammation.
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30020.
    PubMed     Text format     Abstract available


  172. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [J Hepatol 68 (2018) 33-41].
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30013.
    PubMed     Text format    


  173. THIELE M, Rausch V, Fluhr G, Kjaergaard M, et al
    Controlled Attenuation Parameter And Alcoholic Hepatic Steatosis: Diagnostic Accuracy and Role Of Alcohol Detoxification.
    J Hepatol. 2018 Jan 14. pii: S0168-8278(18)30016.
    PubMed     Text format     Abstract available


  174. SPREAFICO C, Sposito C, Vaiani M, Cascella T, et al
    Development of a prognostic score to predict response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30010.
    PubMed     Text format     Abstract available


  175. ORCI LA, Lacotte S, Delaune V, Slits F, et al
    Effects of the gut-liver axis on ischemia-mediated hepatocellular carcinoma recurrence in the mouse liver.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30009.
    PubMed     Text format     Abstract available


  176. LEVADA K, Guldiken N, Zhang X, Vella G, et al
    Hsp72 protects from liver injury via attenuation of hepatocellular death, oxidative stress and JNK-signaling.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30008.
    PubMed     Text format     Abstract available


  177. TURCO L, Garcia-Tsao G, Magnani I, Bianchini M, et al
    Cardiopulmonary hemodynamics and c-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30011.
    PubMed     Text format     Abstract available


  178. THOMAS JA, Ramachandran P, Forbes SJ
    Studies of macrophage therapy for cirrhosis - from mice to men.
    J Hepatol. 2018 Jan 6. pii: S0168-8278(18)30002.
    PubMed     Text format    


    December 2017
  179. UTOH R, Komori J, Kuge H, Tatsumi K, et al
    Adult hepatocytes direct liver organogenesis through non-parenchymal cell recruitment in the kidney.
    J Hepatol. 2017 Dec 26. pii: S0168-8278(17)32531.
    PubMed     Text format     Abstract available


  180. XU B, Jiang M, Chu Y, Wang W, et al
    Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    J Hepatol. 2017 Dec 19. pii: S0168-8278(17)32494.
    PubMed     Text format     Abstract available


  181. LI L, Barry V, Daffis S, Niu C, et al
    Anti-HBV Response to Toll-Like Receptor 7 Agonist GS-9620 is Associated with Intrahepatic Aggregates of T Cells and B Cells.
    J Hepatol. 2017 Dec 14. pii: S0168-8278(17)32490.
    PubMed     Text format     Abstract available


  182. CALDWELL S, Marchesini G
    Cryptogenic vs NASH-cirrhosis: The rose exists well before its name.
    J Hepatol. 2017 Dec 13. pii: S0168-8278(17)32488.
    PubMed     Text format    


  183. OVREHUS ALH, Krarup H, Birkemose I, Holm DK, et al
    Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32475.
    PubMed     Text format    


  184. RATZIU V
    A critical review of endpoints for non-cirrhotic NASH therapeutic trials.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32481.
    PubMed     Text format     Abstract available


  185. VAN VUGT JLA, Alferink LJM, Buettner S, Gaspersz MP, et al
    A Model including Sarcopenia Surpasses the MELD Score in Predicting Waiting List Mortality in Cirrhotic Liver Transplant Candidates.
    J Hepatol. 2017 Dec 5. pii: S0168-8278(17)32474.
    PubMed     Text format     Abstract available


    November 2017
  186. LAU HH, Ng NHJ, Loo LSW, Jasmen J, et al
    The molecular functions of hepatocyte nuclear factors in and beyond the liver.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32451.
    PubMed     Text format     Abstract available


  187. LEE YH, Kim KJ, Yoo ME, Kim G, et al
    Association of nonalcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32448.
    PubMed     Text format     Abstract available


  188. NOBILI V, Mosca A, Scorletti E, Byrne CD, et al
    Reply 'Energy drinks and risk of non alcoholic steatohepatitis'.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32446.
    PubMed     Text format    


  189. ROBIN S, Buchanan R, Poole R
    Energy drinks and adolescents - a hepatic health hazard?
    J Hepatol. 2017 Nov 22. pii: S0168-8278(17)32444.
    PubMed     Text format    


  190. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Is Cryptogenic Cirrhosis Different from NASH Cirrhosis?
    J Hepatol. 2017 Nov 18. pii: S0168-8278(17)32441.
    PubMed     Text format     Abstract available


  191. LEI Z, Xia Y, Si A, Wang K, et al
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection.
    J Hepatol. 2017 Nov 16. pii: S0168-8278(17)32438.
    PubMed     Text format     Abstract available


  192. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    PubMed     Text format     Abstract available


  193. TERZI E, Iavarone M, Pompili M, Veronese L, et al
    Contrast enhanced ultrasound identifies hepatocellular carcinoma in cirrhosis: a large multicenter retrospective study.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32428.
    PubMed     Text format     Abstract available


  194. HU C, Li W, Tian F, Jiang K, et al
    Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
    J Hepatol. 2017 Nov 4. pii: S0168-8278(17)32409.
    PubMed     Text format     Abstract available


  195. HAYES P, Mookerjee RP
    Early TIPS for portal hypertensive related bleeding: Is resource or education the reason for failure to show clear survival benefit?
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32410.
    PubMed     Text format    


    October 2017
  196. MOHAMMED MS, Ferrier G, Abouda G, Corless L, et al
    Socio-economic deprivation significantly impacts clinical management and survival in hepatocellular carcinoma.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32403.
    PubMed     Text format    


  197. ASHHAB AA, Rodin H, Debes JD
    Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant-Authors-reply.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32404.
    PubMed     Text format    


  198. D'AMICO G, Morabito A, D'Amico M, Pasta L, et al
    Clinical states of cirrhosis and competing risks.
    J Hepatol. 2017 Oct 27. pii: S0168-8278(17)32399.
    PubMed     Text format     Abstract available


  199. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    PubMed     Text format     Abstract available


  200. KIM G, Jang SY, Nam CM, Kang ES, et al
    Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32397.
    PubMed     Text format     Abstract available


  201. KIM KM, Han CY, Kim JY, Cho SS, et al
    Galpha12 overexpression induced by miR16 dysregulation contributes to liver fibrosis by promoting autophagy in hepatic stellate cells.
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32388.
    PubMed     Text format     Abstract available


  202. JACKSON R, Psarelli EE, Berhane S, Johnson PJ, et al
    Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32389.
    PubMed     Text format    


  203. BRUIX J, Cheng AL, Llovet J
    Predictors of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32392.
    PubMed     Text format    


  204. NAULT JC, Sutter O, Nahon P, Ganne-Carrie N, et al
    Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations.
    J Hepatol. 2017 Oct 12. pii: S0168-8278(17)32351.
    PubMed     Text format     Abstract available


  205. YU Y, Wang J, Li G, Shen C, et al
    Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?
    J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32346.
    PubMed     Text format    


  206. FUJIWARA N, Friedman SL, Goossens N, Hoshida Y, et al
    Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32328.
    PubMed     Text format     Abstract available


  207. LIM C, Bhangui P, Salloum C, Gavara CG, et al
    Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32331.
    PubMed     Text format     Abstract available


  208. GUSTOT T, Agarwal B
    Selected patients with acute-on-chronic liver failure grade 3 are not too sick to be considered for liver transplantation.
    J Hepatol. 2017;67:667-668.
    PubMed     Text format    


    September 2017
  209. VERHOEVEN CJ, Selten JW, Roest HP, Farid WRR, et al
    Corrigendum to "MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation" [J Hepatol 2013; 59:1231-1238].
    J Hepatol. 2017 Sep 27. pii: S0168-8278(17)32279.
    PubMed     Text format    


  210. GANDHI CR
    Hepatic stellate cell activation and pro-fibrogenic signals.
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32068.
    PubMed     Text format    


  211. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Reply to Letters to the Editor from Mazzarelli et al. entitled "Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything" and Tammineedi et al. entitled "More extended indication of DAA therapy in p
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32292.
    PubMed     Text format    


  212. THABUT D, Pauwels A, Carbonell N, Remy AJ, et al
    Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results.
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32281.
    PubMed     Text format     Abstract available


  213. PRENNER S, Kulik L
    Reply to "Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma".
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32283.
    PubMed     Text format    


  214. HUANG A, Zhao X, Yang XR, Li FQ, et al
    Corrigendum to "Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma" [J Hepatol 67 (2017) 293-301].
    J Hepatol. 2017 Sep 12. pii: S0168-8278(17)32207.
    PubMed     Text format    


  215. MOOKERJEE RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, et al
    Corrigendum to "Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension" [J Hepatol 62 (2015) 325-331].
    J Hepatol. 2017 Sep 8. pii: S0168-8278(17)32209.
    PubMed     Text format    


  216. FANGAZIO S, Camatta D, Minh MT, Ceriani E, et al
    Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma.
    J Hepatol. 2017 Sep 7. pii: S0168-8278(17)32280.
    PubMed     Text format    


  217. IOANNOU GN, Green PK, Berry K
    HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273.
    PubMed     Text format     Abstract available


  218. WANG X, Mao W, Fang C, Tian S, et al
    Dusp14 protects against hepatic ischemia-reperfusion injury via Tak1 suppression.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32275.
    PubMed     Text format     Abstract available


  219. QI X, Liu F, Li Z, Chen S, et al
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277.
    PubMed     Text format    


  220. IRANMANESH P, Toso C
    Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis".
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32274.
    PubMed     Text format    


  221. URBAN SK, Krawczyk M, Willms A, Sanger H, et al
    Diagnostic and Prognostic Role of Circulating Microparticles in Hepatocellular Carcinoma.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32262.
    PubMed     Text format    


  222. MAZZARELLI C, Cannon MD, Belli LS, Agarwal K, et al
    Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32265.
    PubMed     Text format    


  223. HUANG R, Liu Y, Wang J, Xia J, et al
    Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32270.
    PubMed     Text format    


  224. WANG J, Yu Y, Li G, Shen C, et al
    Relationship between serum HBV RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32261.
    PubMed     Text format     Abstract available


  225. WANG M, Shen G, Xu L, Liu X, et al
    IL-1 receptor like 1 protects against alcoholic liver injury by limiting NF-kappaB activation in hepatic macrophages.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32263.
    PubMed     Text format     Abstract available


  226. YIP TC, Chan HL, Wong VW, Wong GL, et al
    Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance".
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32266.
    PubMed     Text format    


  227. PONZIANI FR, Giarretta I, Nicoletti A, Gatto I, et al
    Diagnostic and Prognostic Role of Circulating Microparticles in Hepatocellular Carcinoma.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32257.
    PubMed     Text format    


  228. GROSSI G, Loglio A, Facchetti F, Borghi M, et al
    Tenofovir alafenamide as a Rescue Therapy in a Cirrhotic HBV Patient with a Hystory of Fanconi Syndrome and Multidrug Resistance: A Case Report.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32260.
    PubMed     Text format     Abstract available


    August 2017
  229. SHARMA SA, Kowgier M, Hansen BE, Pieter Brouwer W, et al
    Toronto HCC Risk Index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.
    J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248.
    PubMed     Text format     Abstract available


  230. TORRECILLA S, Sia D, Harrington AN, Zhang Z, et al
    Trunk events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32252.
    PubMed     Text format     Abstract available


  231. CHIANG DY, Villanueva A
    Progress towards molecular patient stratification of hepatocellular carcinoma: lost in translation?
    J Hepatol. 2017 Aug 21. pii: S0168-8278(17)32210.
    PubMed     Text format    


  232. PETTA S, Marchesini G
    Corrigendum to "Coffee and tea breaks for liver health" [J Hepatol 67 (2017) 221-223].
    J Hepatol. 2017 Aug 16. pii: S0168-8278(17)32186.
    PubMed     Text format    


  233. REBOUISSOU S, Zucman-Rossi J, Moreau R, Qiu Z, et al
    Note of caution: contaminations of hepatocellular cell lines.
    J Hepatol. 2017 Aug 11. pii: S0168-8278(17)32206.
    PubMed     Text format    


  234. DONATO MF, Invernizzi F, Rossi G, Iavarone M, et al
    Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32200.
    PubMed     Text format    


  235. MAJUMDAR A, Bailey M, Kemp WM, Bellomo R, et al
    Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32198.
    PubMed     Text format     Abstract available


  236. WAZIRY R, Hajarizadeh B, Grebely J, Amin J, et al
    Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199.
    PubMed     Text format     Abstract available


  237. DONG YANG J, Leise MD
    Reply to " Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
    J Hepatol. 2017 Aug 8. pii: S0168-8278(17)32201.
    PubMed     Text format    


  238. SEBASTIAN M, Johannes M
    Is Room Temperature Susceptometry really an accurate method to assess hepatocellular iron? A response.
    J Hepatol. 2017 Aug 7. pii: S0168-8278(17)32192.
    PubMed     Text format    


  239. PAISANT A, Laine F, Gandon Y, Bardou-Jacquet E, et al
    Is Room Temperature Susceptometer really an accurate method to assess hepatocellular iron?
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32193.
    PubMed     Text format    


  240. THALHEIMER U, Giannelli V, Maimone S
    Non selective beta blockers in cirrhosis.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32194.
    PubMed     Text format    


  241. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Erratum to "Human liver regeneration in advanced cirrhosis is organized by the portal tree" [J Hepatol 66 (2017) 778-786].
    J Hepatol. 2017;67:430-436.
    PubMed     Text format    


    July 2017
  242. LEE S, Kim SH
    Reply to: "How to Better Predict Microvascular Invasion and Recurrence of Hepatocellular Carcinoma".
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32156.
    PubMed     Text format    


  243. XU XF, Yu JJ, Xing H, Shen F, et al
    How to Better Predict Microvascular Invasion and Recurrence of Hepatocellular Carcinoma.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32157.
    PubMed     Text format    


  244. BERG T, Simon KG, Mauss S, Schott E, et al
    Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32155.
    PubMed     Text format     Abstract available


  245. LEE WM
    Public Health: Acetaminophen (APAP) Hepatotoxicity- Isn't It Time for APAP to Go Away?
    J Hepatol. 2017 Jul 19. pii: S0168-8278(17)32148.
    PubMed     Text format     Abstract available


  246. NAULT JC, Paradis V, Cherqui D, Vilgrain V, et al
    Molecular classification of hepatocellular adenoma in clinical practice.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32152.
    PubMed     Text format     Abstract available


  247. PIANO S, Tonon M, Vettore E, Stanco M, et al
    Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32151.
    PubMed     Text format     Abstract available


  248. ZHANG S, Song X, Cao D, Xu Z, et al
    Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma induced in mice by AKT and Yap co-expression.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32149.
    PubMed     Text format     Abstract available


  249. KOLLY P, Waidmann O, Vermehren J, Moreno C, et al
    Hepatocellular Carcinoma Recurrence after Direct Antiviral Agent Treatment: a European Multicentre Study.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32150.
    PubMed     Text format    


  250. ROBERTO C, Valeria R, Cristina N, Simona B, et al
    Gut-derived endotoxin stimulates factor viii secretion from endothelial cells. implications for hypercoagulability in cirrhosis.
    J Hepatol. 2017 Jul 14. pii: S0168-8278(17)32145.
    PubMed     Text format     Abstract available


  251. FICKERT P, Wagner M
    Biliary bile acids in hepatobiliary injury - What is the link?
    J Hepatol. 2017 Jul 13. pii: S0168-8278(17)32008.
    PubMed     Text format     Abstract available


  252. GAVRIILIDIS P, Roberts KJ, Askari A, Sutcliffe RP, et al
    Evaluation of the Current Guidelines for Resection of hepatocellular carcinoma Using the Appraisal of Guidelines Research and Evaluation II Instrument.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32136.
    PubMed     Text format     Abstract available


  253. STENGEL S, Stallmach A, Richter K, Landrock A, et al
    Serum metabolic signatures in patients with overt hepatic encephalopathy.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32138.
    PubMed     Text format    


  254. WEISS N, Colsch B, Fenaille F, Junot C, et al
    Metabolic signature for severe cirrhosis with inflammation or hepatic encephalopathy: do we really face two different entities?
    J Hepatol. 2017 Jul 5. pii: S0168-8278(17)32140.
    PubMed     Text format    


  255. BRUIX J, Cheng AL, Meinhardt G, Nakajima K, et al
    Prognostic Factors and Predictors of Sorafenib Benefit in Patients With Hepatocellular Carcinoma: Analysis of Two Phase 3 Studies.
    J Hepatol. 2017 Jul 4. pii: S0168-8278(17)32134.
    PubMed     Text format     Abstract available


  256. SAMJI H, Yu A, Kuo M, Alavi M, et al
    Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
    J Hepatol. 2017 Jul 3. pii: S0168-8278(17)32133.
    PubMed     Text format     Abstract available


    June 2017
  257. BECK M, Schirmacher P, Singer S
    Alterations of the nuclear transport system in hepatocellular carcinoma - new basis for therapeutic strategies.
    J Hepatol. 2017 Jun 30. pii: S0168-8278(17)32122.
    PubMed     Text format     Abstract available


  258. YIP TC, Chan HL, Wong VW, Tse YK, et al
    Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Jun 23. pii: S0168-8278(17)32092.
    PubMed     Text format     Abstract available


  259. MARIN V, Poulsen K, Odena G, McMullen MR, et al
    Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32086.
    PubMed     Text format     Abstract available


  260. XIANG X, You XM, Zhong JH, Li LQ, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32081.
    PubMed     Text format    


  261. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    PubMed     Text format     Abstract available


  262. ARTRU F, Louvet A, Ruiz I, Levesque E, et al
    Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32079.
    PubMed     Text format     Abstract available


  263. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    RE: Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32084.
    PubMed     Text format    


  264. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32074.
    PubMed     Text format    


  265. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32075.
    PubMed     Text format    


  266. PANG Q, Liu HC, Zhou L, Jin H, et al
    Inappropriateuse of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32082.
    PubMed     Text format    


  267. NAGATA H, Nakagawa M, Asahina Y, Sato A, et al
    Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    J Hepatol. 2017 Jun 13. pii: S0168-8278(17)32070.
    PubMed     Text format     Abstract available


  268. KALAMBOKIS GN, Baltayannis G, Christodoulou D, Christou L, et al
    Beta adrenergic blockade and advanced cirrhosis: does it really improve survival in patients with acute-on-chronic liver failure?
    J Hepatol. 2017 Jun 6. pii: S0168-8278(17)32064.
    PubMed     Text format    


    May 2017
  269. TERATANI T, Tomita K, Suzuki T, Furuhashi H, et al
    Free cholesterol accumulation in liver sinusoidal endothelial cells exacerbates acetaminophen hepatotoxicity via TLR9 signaling.
    J Hepatol. 2017 May 26. pii: S0168-8278(17)32056.
    PubMed     Text format     Abstract available


  270. LU Z, Zuo B, Jing R, Gao X, et al
    Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
    J Hepatol. 2017 May 23. pii: S0168-8278(17)32055.
    PubMed     Text format     Abstract available


  271. CALDERARO J, Couchy G, Imbeaud S, Amaddeo G, et al
    Histological Subtypes of Hepatocellular Carcinoma Are Related To Gene Mutations and Molecular Tumour Classification.
    J Hepatol. 2017 May 19. pii: S0168-8278(17)32050.
    PubMed     Text format     Abstract available


  272. PEMBROKE T, Deschenes M, Lebouche B, Benmassaoud A, et al
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32047.
    PubMed     Text format     Abstract available


  273. DE GALARRETA MR, Lujambio A
    Therapeutic editing of hepatocyte genome in vivo.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32048.
    PubMed     Text format     Abstract available


  274. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    PubMed     Text format    


  275. WANG Q, Lv Y, Bai M, Wang Z, et al
    Eight millimeter covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding.
    J Hepatol. 2017 May 12. pii: S0168-8278(17)32015.
    PubMed     Text format     Abstract available


  276. ASHHAB AA, Rodin H, Powell J, Debes JD, et al
    Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant.
    J Hepatol. 2017 May 10. pii: S0168-8278(17)32012.
    PubMed     Text format    


  277. SHIN WJ, Hwang GS
    Reply to: "Pressure volume curves in cirrhosis: more than meets the eye".
    J Hepatol. 2017 May 9. pii: S0168-8278(17)32010.
    PubMed     Text format    


  278. RIPOLL C, Yotti R, Banares R, Bermejo J, et al
    Pressure Volume Curves in Cirrhosis: more than meets the eye.
    J Hepatol. 2017 May 8. pii: S0168-8278(17)32006.
    PubMed     Text format    


  279. TAN-GARCIA A, Wai LE, Zheng D, Ceccarello E, et al
    Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32004.
    PubMed     Text format     Abstract available


  280. LEE S, Kim SH, Lee JE, Sinn DH, et al
    Preoperative Gadoxetic acid-enhanced MRI for Predicting Microvascular Invasion in Patients with Single hepatocellular carcinoma.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32005.
    PubMed     Text format     Abstract available


  281. MUELLER J, Raisi H, Rausch V, Peccerella T, et al
    Sensitive and non-invasive assessment of hepatocellular iron using a novel room-temperature susceptometer.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32000.
    PubMed     Text format     Abstract available


  282. NADIM MK, DiNorcia J, Ji L, Groshen S, et al
    Inequity In Organ Allocation For Patients Awaiting Liver Transplantation: Rationale for Uncapping the Model for End-Stage Liver Disease.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32003.
    PubMed     Text format     Abstract available


  283. VAUTHEY JN, Mizuno T, Overman MJ, Soubrane O, et al
    Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside?
    J Hepatol. 2017 May 2. pii: S0168-8278(17)30252.
    PubMed     Text format    


  284. MOSCA A, Nobili V, De Vito R, Crudele A, et al
    Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents.
    J Hepatol. 2017;66:1031-1036.
    PubMed     Text format     Abstract available


  285. SANDBOTHE M, Buurman R, Reich N, Greiwe L, et al
    The microRNA-449 family inhibits TGF-beta-mediated liver cancer cell migration by targeting SOX4.
    J Hepatol. 2017;66:1012-1021.
    PubMed     Text format     Abstract available


  286. KARLAS T, Petroff D, Sasso M, Fan JG, et al
    Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
    J Hepatol. 2017;66:1022-1030.
    PubMed     Text format     Abstract available


  287. HUANG K, Du M, Tan X, Yang L, et al
    PARP1-mediated PPARalpha poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    J Hepatol. 2017;66:962-977.
    PubMed     Text format     Abstract available


    April 2017
  288. KLINGENBERG M, Matsuda A, Diederichs S, Patel T, et al
    Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30250.
    PubMed     Text format     Abstract available


  289. BRITO-AZEVEDO A
    Carvedilol and survival in cirrhosis with ascites: a cognitive bias?
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30219.
    PubMed     Text format    


  290. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed     Text format    


  291. SEIDEL RA, Claudel T, Schleser FA, Ojha NK, et al
    Impact of higher-order heme degradation products on hepatic function and hemodynamics.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30208.
    PubMed     Text format     Abstract available


  292. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Text format     Abstract available


  293. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    PubMed     Text format     Abstract available


  294. TAPPER EB, Sengupta N
    Testing for elevated liver enzymes: central to clinical Hepatology but in need of more data.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30199.
    PubMed     Text format    


  295. CARUSO S, Calderaro J, Letouze E, Nault JC, et al
    Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
    J Hepatol. 2017;66:734-742.
    PubMed     Text format     Abstract available


  296. KOPEC AK, Joshi N, Cline-Fedewa H, Wojcicki AV, et al
    Fibrin(ogen) drives repair after acetaminophen-induced liver injury via leukocyte alphaMbeta2 integrin-dependent upregulation of Mmp12.
    J Hepatol. 2017;66:787-797.
    PubMed     Text format     Abstract available


  297. WOOLBRIGHT BL, Jaeschke H
    Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure.
    J Hepatol. 2017;66:836-848.
    PubMed     Text format     Abstract available


  298. FERRERE G, Wrzosek L, Cailleux F, Turpin W, et al
    Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
    J Hepatol. 2017;66:806-815.
    PubMed     Text format     Abstract available


    March 2017
  299. KIM JY, Park KJ, Hwang JY, Kim GH, et al
    Activating Transcription Factor 3 Is a Target Molecule Linking Hepatic Steatosis to Impaired Glucose Homeostasis.
    J Hepatol. 2017 Mar 29. pii: S0168-8278(17)30187.
    PubMed     Text format     Abstract available


  300. QURINO L, Massimo R, Jan L
    Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?
    J Hepatol. 2017 Mar 24. pii: S0168-8278(17)30180.
    PubMed     Text format    


  301. BHAT M, Ghali P, Bilodeau M
    Reply to: "Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?"
    J Hepatol. 2017 Mar 24. pii: S0168-8278(17)30183.
    PubMed     Text format    


  302. PREZIOSI ME, Singh S, Valore EV, Jung CL, et al
    Mice lacking liver-specific beta-catenin develop steatohepatitis and fibrosis after iron overload.
    J Hepatol. 2017 Mar 21. pii: S0168-8278(17)30146.
    PubMed     Text format     Abstract available


  303. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Mar 20. pii: S0168-8278(17)30145.
    PubMed     Text format     Abstract available


  304. URBAN TJ, Nicoletti P, Chalasani N, Serrano J, et al
    Minocycline Hepatotoxicity: Clinical characterization and identification of HLA-B * 35:02 as a risk factor.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30144.
    PubMed     Text format     Abstract available


  305. HUANG A, Zhao X, Yang XR, Li FQ, et al
    Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30139.
    PubMed     Text format     Abstract available


  306. VILARINHO S, Erson-Omay Z, Mitchell-Richards K, Cha C, et al
    Exome Analysis of the Evolutionary Path of Hepatocellular Adenoma-Carcinoma Transition, Vascular Invasion and Brain Dissemination.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30143.
    PubMed     Text format     Abstract available


  307. PATOURAUX S, Rousseau D, Bonnafous S, Lebeaupin C, et al
    CD44 is a key player in non-alcoholic steatohepatitis.
    J Hepatol. 2017 Mar 16. pii: S0168-8278(17)30137.
    PubMed     Text format     Abstract available


  308. JOSHI D, Gupta N, Samyn M, Deheragoda M, et al
    The management of childhood liver diseases in adulthood.
    J Hepatol. 2017;66:631-644.
    PubMed     Text format     Abstract available


  309. LACKNER C, Spindelboeck W, Haybaeck J, Douschan P, et al
    Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease.
    J Hepatol. 2017;66:610-618.
    PubMed     Text format     Abstract available


  310. RAMIREZ T, Li YM, Yin S, Xu MJ, et al
    Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression.
    J Hepatol. 2017;66:601-609.
    PubMed     Text format     Abstract available


  311. LUKACS-KORNEK V, Lammert F
    The progenitor cell dilemma: Cellular and functional heterogeneity in assistance or escalation of liver injury.
    J Hepatol. 2017;66:619-630.
    PubMed     Text format     Abstract available


  312. SPIRLI C, Mariotti V, Villani A, Fabris L, et al
    Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
    J Hepatol. 2017;66:571-580.
    PubMed     Text format     Abstract available


  313. LANGIEWICZ M, Schlegel A, Saponara E, Linecker M, et al
    Hedgehog pathway mediates early acceleration of liver regeneration induced by a novel two-staged hepatectomy in mice.
    J Hepatol. 2017;66:560-570.
    PubMed     Text format     Abstract available


    February 2017
  314. NAKAGAWA R, Muroyama R, Saeki C, Goto K, et al
    miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30066.
    PubMed     Text format     Abstract available


  315. TREBICKA J
    Emergency TIPS in a Child-Pugh B patient: When does the window of opportunity open and close?
    J Hepatol. 2017;66:442-450.
    PubMed     Text format     Abstract available


  316. MA J, Hwang SJ, Pedley A, Massaro JM, et al
    Bi-directional analysis between fatty liver and cardiovascular disease risk factors.
    J Hepatol. 2017;66:390-397.
    PubMed     Text format     Abstract available


  317. TAPPER EB, Saini SD, Sengupta N
    Extensive testing or focused testing of patients with elevated liver enzymes.
    J Hepatol. 2017;66:313-319.
    PubMed     Text format     Abstract available


    January 2017
  318. HASHIDA R, Kawaguchi T, Bekki M, Omoto M, et al
    Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review.
    J Hepatol. 2017;66:142-152.
    PubMed     Text format     Abstract available


  319. STICKEL F, Moreno C, Hampe J, Morgan MY, et al
    The genetics of alcohol dependence and alcohol-related liver disease.
    J Hepatol. 2017;66:195-211.
    PubMed     Text format     Abstract available


  320. GARIANI K, Ryu D, Menzies KJ, Yi HS, et al
    Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease.
    J Hepatol. 2017;66:132-141.
    PubMed     Text format     Abstract available


  321. GUIXE-MUNTET S, de Mesquita FC, Vila S, Hernandez-Gea V, et al
    Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury.
    J Hepatol. 2017;66:86-94.
    PubMed     Text format     Abstract available


  322. POISSON J, Lemoinne S, Boulanger C, Durand F, et al
    Liver sinusoidal endothelial cells: Physiology and role in liver diseases.
    J Hepatol. 2017;66:212-227.
    PubMed     Text format     Abstract available


  323. HOCQUELET A, Aube C, Rode A, Cartier V, et al
    Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC.
    J Hepatol. 2017;66:67-74.
    PubMed     Text format     Abstract available


    December 2016
  324. CRUZ-LEMINI M, Altamirano J, Ndugga N, Abraldes JG, et al
    Reply to: Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30756.
    PubMed     Text format    


  325. AYUBI E, Safiri S, Sani M, Khazaei S, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30758.
    PubMed     Text format    


  326. ARROYO V, Moreau R
    Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis.
    J Hepatol. 2016 Dec 15. pii: S0168-8278(16)30577.
    PubMed     Text format    


    November 2016
  327. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed     Text format    


    October 2016
  328. WANNHOFF A, Friedrich K, Gotthardt DN
    Reduced influence of procoagulant changes on survival in patients with advanced cirrhosis.
    J Hepatol. 2016 Oct 24. pii: S0168-8278(16)30583.
    PubMed     Text format    


  329. POTZE W, Sanyal AJ, Lisman T
    How to assess hemostatic capacity in patients with cirrhosis?
    J Hepatol. 2016 Oct 18. pii: S0168-8278(16)30576.
    PubMed     Text format    


    September 2016
  330. FUCHS CD, Paumgartner G, Wahlstrom A, Schwabl P, et al
    Metabolic Preconditioning Protects BSEP/ABCB11-/- Mice against Cholestatic Liver Injury.
    J Hepatol. 2016 Sep 1. pii: S0168-8278(16)30482.
    PubMed     Text format     Abstract available


    July 2016
  331. PAIS R, Sidney Barritt A 4th, Calmus Y, Scatton O, et al
    Nafld and liver transplantation: current burden and expected challenges.
    J Hepatol. 2016 Jul 30. pii: S0168-8278(16)30403.
    PubMed     Text format     Abstract available


    May 2016
  332. VERKADE HJ, Bezerra JA, Davenport M, Schreiber RA, et al
    Biliary atresia and other cholestatic childhood diseases: advances and future challenges.
    J Hepatol. 2016 May 6. pii: S0168-8278(16)30186.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: